All Oncology News

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

Florida Cancer Specialists & Research Institute spotlights a study uncovering a new testing method to determine personalized care options in NSCLC.

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.

Emavusertib monotherapy was tolerable and produced responses in patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

Aditya Bardia, MD, MPH, FASCO, discusses the evolving role of T-DXd for patients with HER2-positive advanced breast cancer.

Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.

Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more.

Sid Devarakonda, MD, details how new treatment strategies in the neoadjuvant and adjuvant settings are being implemented in the non–small cell lung cancer arena.

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami.

Toripalimab in combination with etoposide and platinum has been approved by the NMPA in China in first-line extensive-stage small cell lung cancer.

Capivasertib plus paclitaxel did not improve OS vs paclitaxel in locally advanced or metastatic TNBC or patients with PIK3CA, AKT1, or PTEN alterations.

As investigators continue efforts to improve outcomes for patients with low-grade serous ovarian cancer, they are expanding investigations beyond chemotherapy.

A survey of adult patients with chronic lymphocytic leukemia demonstrated that respondents preferred therapies that increased PFS vs other attributes.

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

The FDA placed a partial clinical hold on a phase 1 trial evaluating YL202 in select patients with advanced non–small cell lung cancer or breast cancer.